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Understanding where the greatest risk to a herd
is relative to the introduction of bovine viral diarrhea
(BVD) virus, is paramount to controlling or preventing
economic losses to BVD. One of the first steps in the
risk assessment process is determining if BVDv is
present in the herd.
The virus can be present in the herd as transient
infections or through persistently-infected animals.
Transient infections are those acute viral episodes that
infects the animal, to which the animal then mounts an
immune response which often eliminates the disease
from the animal following a period of reduced
productivity due to the fact that the animal’s immune
system is trying to eliminate the virus. These infections
can be spread from animal to animal depending on herd
immunity.
Persistant infections, on the other hand, are
caused by animals who are infected with disease in
utero. When exposed during the critical window of time
between the second and fifth month of gestation, the
naïve fetal immune system may not recognize the virus
as foreign. In this scenerio the virus is identified by the
immune system as “self” or “normal” and thus the fetus
and subsequent calf becomes persistently infected (PI).
These PI animals shed the virus when born in
remarkable amounts. While transient infections are most
commonly found in herds, PI animals can add
significantly to a herd’s viral load when present.
The first box of Figure 1 ranks the cost and
reliability of different techniques used to determine if the
virus is circulating within the herd; ranked from least
reliable (top) to most reliable (bottom). For example, the
observation for clincial signs is much less costly and
reliable than submiting biological (i.e, ear) samples for
testing.
If BVDv is circulating in the herd the main
objective becomes biocontainment. Biocontainment is

simply defined as processes and procedures
implemented to prevent further exposure or risk from a
known disease or issue. With BVDv, the second box of
Figure 1 illustrates two objectives to consider in
biocontainment. These include minimizing the negative
impact of infection and the elimination of circulating
virus within the herd.
Vaccination and testing are critical components
in biocontainment as it relates to BVD. The overall
objective with these two tools is to increase herd
immunity through vaccination and to identify PI’s
through testing. There are two different types of vaccines
available for use against BVDv, they are commonly
referred to as “killed” or “modified-live.” There are pros
and cons to using either inactivated (killed) or attenuated
(modified live) vaccine preparations. Table 1 dicusses
the advantages and disadvantages of both.
There are several methods used to diagnose the
virus in the herd. Table 2 organizes these tests and
discusses some of the limitations of each. The most
common sample submitted is an ear notch, and the most
common test preformed is antigen-capture ELISA
(ACE). ACE testing of ear notches seems to be very
reliable and has a relative low cost when compared to
others. Ears are handy to sample from, but any skin
sample will suffice.
Vaccination timing plays a large role in
minimizing risk. Figure 2 illustrates the most and least
reliable vaccination schedules and timing to prevent
disease in calves and heifers. It is recommneded that
vaccinating calves early (4 months of age) and often
(giving boosters) will increase their immunity and
decrease the risk for disease (Figure 2). For heifers and
cows, making sure that they are boostered with a
modified live BVDv vaccine, 30 days prior to breeding
is the more reliable management pracatice for preventing
PI calf development (Figure 2).

Table 1. Different Bovine Viral Diarrhea vaccine types.

Bulls have been proven to transmit the disease
both in semen and by direct contact. Do not forget to
address disease mitigation in the bulls in the herd
through development of a vaccine program for them that
best reduces risk (Figure 2). The best recommendation
includes the use of a cytopathic modified live virus in
bulls. Bulls vaccinated with non-cyctopathic vaccine
have shed virus in their semen. Most U.S. common
modified live BVDv vaccines contain only cyctopathic
strains of BVDv.
If virus is not circulating in the herd, then
biosecurity becomes very important in minimizing the
risk for introduction of the virus. Figure 1 suggests the
most reliable management practices for reducing the risk
of BVDv introduction. Initiating all of the
recommendations of biosecurity in Figure 1 should
reduce or eliminate most of the risk. Testing all
replacement animals and implementing a strict 21-day
quarantine is the most reliable way to minimize risk.
This suggestion may also be the most restrictive.
This information is intended to be used as a
reference from which to start the conversation for
establishing management procedures to prevent loss
from BVDv. In summary, understanding the risk for

BVDv to your herd is critical to preventing, controlling,
or eradicating the disease. The first step is to determine
if the virus is already present in the herd. There are more
reliable methods to help you determine if BVDv is
present, with targeted testing being the most reliable and
most costly (Figure 1). Depending on the answer to the
question, “Is BVDv present?” you will either want to
consider implementing principles of biocontainment
(virus present) or biosecurity (virus not present) (Figure
1). Vaccination can be a good tool in minimizing the
impact of BVDv in the herd or to be used in helping to
prevent the development of PI animals. In general, using
a modified-live virus preparation early and often
(including 30 days prior to breeding in heifers) is the
most reliable way to prevent PI animals (Figure 2).
Remember, there are considerations to be aware of when
choosing between the two types of vaccines (Table 1).
For further information concerning the
prevalence of BVDv in your area, and for help in
designing a vaccination/testing program for your herd,
please consult your local veterinarian.

Table 2. Summary of BVDV diagnostic tests and their uses.*
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